Anusha Sinha

Introduction Choosing a CDMO for Long Acting Injectable Formulation Development is an important strategic decision in modern drug delivery. These […]

Introduction: Long Acting Injectable Formulation Development is becoming a preferred strategy for pharmaceutical companies aiming to improve patient adherence and

Introduction: Why Long Acting Injectables Market Trends Are Shifting the Generic Pharma Calculus The Long Acting Injectables Market Trends observed

Choosing the right Contract Research Organization (CRO) for complex injectables is a strategic decision that goes far beyond basic outsourcing.

Introduction: Why Lupron Depot Development Failures Persist Lupron Depot Development Failures continue to shape the reality of long-acting injectable (LAI)

Introduction: Why Risk Allocation Matters More Than Risk Avoidance in Generic Development In complex generic pharmaceutical development, risk cannot be

Introduction: Why Generic Injectable Co-Development Is Critical for Depot Injectables Generic Injectable Co-Development is no longer just an option—it is

Introduction: Why LAI ANDAs Demand More Than a CRO or CDMO Alone The generic pathway for Long-Acting Injectables (LAIs), including

Introduction: The Regulatory Pathway for Complex Peptide Injectables is a multi-faceted compliance framework that requires developers to establish therapeutic equivalence